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Original articleTissue-selective estrogen complexes with
bazedoxifene prevent metabolic dysfunction
in female miceJun Ho Kim 1,5, Matthew S. Meyers 1, Saja S. Khuder 2, Simon L. Abdallah 2, Harrison T. Muturi 2, Lucia Russo 2,
Chandra R. Tate 4, Andrea L. Hevener 3, Sonia M. Najjar 2, Corinne Leloup 1,6, Franck Mauvais-Jarvis 1,4,*ABSTRACTPairing the selective estrogen receptor modulator bazedoxifene (BZA) with estrogen as a tissue-selective estrogen complex (TSEC) is a novel
menopausal therapy. We investigated estrogen, BZA and TSEC effects in preventing diabetisity in ovariectomized mice during high-fat feeding.
Estrogen, BZA or TSEC prevented fat accumulation in adipose tissue, liver and skeletal muscle, and improved insulin resistance and glucose
intolerance without stimulating uterine growth. Estrogen, BZA and TSEC improved energy homeostasis by increasing lipid oxidation and energy
expenditure, and promoted insulin action by enhancing insulin-stimulated glucose disposal and suppressing hepatic glucose production. While
estrogen improved metabolic homeostasis, at least partially, by increasing hepatic production of FGF21, BZA increased hepatic expression of
Sirtuin1, PPARα and AMPK activity. The metabolic beneﬁts of BZA were lost in estrogen receptor-α deﬁcient mice. Thus, BZA alone or in TSEC
produces metabolic signals of fasting and caloric restriction and improves energy and glucose homeostasis in female mice.
& 2014 The Authors. Published by Elsevier GmbH.
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With the dramatic increase in life expectancy, many women will spend a
large part of their lives in a post-menopausal state. Apart from causing
degeneration of the cardiovascular, skeletal and central nervous systems
[1,2], estrogen deﬁciency also increases risk for metabolic syndrome and
type 2 diabetes [3]. Overall, the role of estrogen deﬁciency to the
pathophysiology of chronic diseases in women is emerging as a novel
therapeutic challenge that parallels the increased risk associated with
conventional estrogen replacement protocols [4]. It is against this backdrop
that novel therapeutic strategies targeting estrogen receptor in non-
reproductive tissues may offer therapeutic beneﬁts that reduce metabolic
dysfunction associated with both ovarian failure and estrogen deﬁciency.http://dx.doi.org/10.1016/j.molmet.2013.12.009
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Original articleindicates that TSEC therapy consisting of the combination of CE and BZA
[Duavee (TM)] [14] is an effective alternative to conventional hormone
therapy for treatment of postmenopausal symptoms and prevention of
osteoporosis [15,16]. However, there is currently no information on the
efﬁcacy of TSEC with BZA in preventing postmenopausal metabolic
disorders. In a series of experiments that replicated postmenopausal
metabolic derangements observed in older women, we investigated the
effect of BZA paired with estrogens [CE or 17β-estradiol (E2)] on glucose
and energy homeostasis in ovariectomized (OVX) mice fed a high-fat
diet (HFD).2. MATERIALS AND METHODS
2.1. Animals and surgery
Female C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine),
7 weeks of age, were housed with a 12-h light–dark cycle. After a 1-
week acclimation period, mice were randomly divided into seven
treatment groups as follows: (1) sham vehicle; (2) OVXþvehicle;
(3) OVXþCE; (4) OVXþE2; (5) OVXþBZA; (6) OVXþCEþBZA;
(7) OVXþE2þBZA. Mice were subjected to bilateral OVX or sham
operation under anesthesia with 1.2% Avertin solution (i.p.). Treatment
with CE, BZA, TSEC or vehicle was initiated on the day of surgery. In four
separate studies, all compounds were administered orally to mice once
daily for 8 weeks with vehicle (saline, 2% Tween 80, 0.5% methylcel-
lulose), CE 2.5 mg/kg, BZA 3 mg/kg or CE 2.5 mgþBZA 3 mg/kg in
saline. The dosages or concentrations of CE and BZA administered
provided for the optimal maintenance of estrogen action in absence of
uterine growth [11,13]. During the ovariectomy procedure, a 90-day
release E2 pellet (0.5 mg/pellet, Innovation Research of America,
Sarasota, FL) was implanted subcutaneously on the dorsal aspect of
the neck of each animal. All mice were provided phytoestrogen-free HFD
(TD04059, 52% Kcal from anhydrous milk fat, Harland Teklad, Madison,
WI) and water ad libitum during the experimental period. At the end of
the study (day 29 or day 57), mice were euthanized by an overdose of
Avertin, and blood was collected by cardiac puncture. Mice with a null
mutation of the estrogen receptor α (ERα / ) were generated as
previously described [17]. All animal work was performed in compliance
with the Institutional Animal Care and Use Committee at Northwestern
University.2.2. Biochemical assays
Following euthanasia, serum was separated by centrifugation at 3000g
for 20 min at 4 1C and used for determination leptin, adiponectin, RBP4,
Lcn2 and FGF21 using commercial ELISA kits, RBP4 (Abnova Co.,
Walnut, CA), Lcn2 (R&D Systems Inc., Minneapolis, MN), leptin,
adiponectin and FGF21 (Millipore Co., Billerica, MA) as speciﬁed by
the manufacturer. TBARS was measured in serum using a commercial
kit (ZeptoMetrix Co., Buffalo, NY). For hepatic TG measurement, tissue
saponiﬁcation in ethanolic KOH and neutralization with MgCl2 were
performed as previously described [18]. Glycerol content was deter-
mined by enzymatic colorimetric methods using a commercially
available kit (Sigma-Aldrich, St. Louis, MO). For the measurements of
phosphorylated (T172) AMP-activated protein kinase α (AMPKα) in liver
and muscle, total protein were extracted from liver and gastrocnemius
muscle using tissue extraction reagent I (Invitrogen, Camarillo, CA).
AMPKα [pT172] was measured by an ELISA kit (Invitrogen) as speciﬁed
by the manufacturer. Insulin-stimulated Akt activity was measured in
lysates from liver and muscle collected following the clamp study using178 MOLECULAR METABOLISM 3 (2014) 177–190 & 2014 The Auwestern blotting of Akt phosphorylation (S473) (Cell Signaling) and
expression (Cell Signaling).
2.3. Histological staining
Sections of parametrial adipose tissue and liver were ﬁxed in 10%
formalin, embedded in parafﬁn, sectioned and stained with H&E.
Adipocyte area was traced and quantiﬁed in 300 cells per mouse using
ImageJ software (National Institute of Health, NIH Version v1.32j). The
relative adipocyte number was calculated by dividing parametrial fat pad
weight by the mean adipocyte size in each mouse (n¼4/group) as
described [19].
2.4. Studies of energy homeostasis
Food intake, locomotor activity and energy expenditure were analyzed
using an indirect-calorimetric system (Labmaster, TSE Systems, Bad
Homburg, Germany) in the mouse metabolic phenotyping core at
Northwestern University. Mice were subjected to bilateral OVX surgery
and received daily drug treatments with vehicle, CE, BZA or CEþBZA as
described above for 4 weeks. Mice were then individually placed in air-
tight respiratory chambers at a constant temperature (24.070.5 1C)
and were acclimatized to the metabolic cages for 3 days before
measurements. Energy expenditure was measured by indirect calori-
metry, while locomotor activity was assessed using an infrared light
beam detection system for horizontal and vertical activity. Data were
collected every 30 min and averaged over the 3-day period. Energy
expenditure was calculated from O2 consumption and CO2 production
and normalized to fat-free mass. Oral drug treatments were performed
at 10:00 am every day during metabolic caging.
2.5. Real-time ﬂuorescent Q-PCR
Perigonadal WAT, BAT, liver and skeletal muscle tissues were homo-
genized in 1 mL of TRIzol reagent and then total RNA was isolated. Total
RNA was reverse transcribed to cDNA using a iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA). cDNA was used as a template for the relative
quantitation for the selected target genes with predesigned TaqMan
gene expression assay kits. Each 20 μL reaction contained 100 ng
cDNA, 2 TaqMan Fast Advanced Mastermix (Applied Biosystems,
Carlsbad, CA), forward and reverse primers and TaqMan probe. All
reactions were carried out in triplicate with the LightCyclers 480 II Real-
Time PCR System (Roche, Mannheim, Germany) using the following
conditions: 50 1C for 2 min and 95 1C for 20 s followed by 40 cycles of
95 1C for 3 s and 60 1C for 30 s. Results were expressed as a relative
value after normalization to 18S rRNA.
2.6. FAS enzymatic activity
FAS activity was measured by the incorporation of radiolabeled malonyl-
CoA into palmitate as described previously [20]. Brieﬂy, 60–100 mg of
liver tissue was homogenized in buffer (20 mM Tris, pH 7.5; 1.0 mM
EDTA; 1.0 mM DTT; and phosphatase and protease inhibitors) and
centrifuged at 12,000g for 30 min at 4 1C. The supernatant was
incubated for 20 min at 37 1C with 166.6 μM acetyl-CoA, 100 mM
potassium phosphate (pH 6.6), 0.1 μCi [14C] malonyl-CoA, and 25 nM
malonyl-CoA in the absence or presence of 500 μM NADPH. The
reaction was stopped with 1:1 chloroform/methanol solution, mixed for
30 min at 20 1C, and centrifuged at 12,500g for 30 min. The super-
natant was vacuum-dried, and the pellet was resuspended in 200 μL
water-saturated butanol. After addition of 200 μL ddH2O, vortexing, and
spinning for 1 min, the upper layer was removed for re-extraction. The
butanol layer was dried and counted. Protein was quantiﬁed by Bio-Radthors. Published by Elsevier GmbH. www.molecularmetabolism.comOpen access under CC BY-NC-ND license.
protein assay, and results were expressed as relative cpm of [14C]
incorporated per microgram protein.2.7. Physiological studies of glucose homeostasis
Random-fed blood glucose was measured between at 9:00 am using
OneTouch Ultra 2 glucose meter (LifeScan, Inc., Milpitas, CA). For insulin
levels, blood samples were collected from the tail vein in a heparinized
microcapillary tube (Drummond Scientiﬁc, Broomall, PA) at week 4.
Plasma insulin was measured using an ELISA kit (Millipore Co., Billerica,
MA). OGTT was performed as described previously [21] with some
modiﬁcation. After 8-h fasting, a glucose load was administered orally
(2 g/kg). For insulin tolerance test (ITT), after 6-h fasting, mice received
an i.p. injection of 0.5 U/kg human insulin (Humalog, Lilly, Indianapolis,
IN) in PBS. For pyruvate tolerance test (PTT), after 18-h fasting, mice
received an i.p. injection of 2 g/kg sodium pyruvate (Sigma) dissolved in
PBS. During OGTT, ITT and PTT, blood glucose levels were measured
from the tail vein as indicated above. The measurement of insulin
concentration during OGTT was done at the indicated times and as
described above. The area-under the curve (AUC) was calculated for
glucose and insulin for each group of animals during OGTT, ITT and PTT.2.8. Euglycemic-hyperinsulinemic clamp
After 5 weeks of treatment, mice were anesthetized with 1.2% Avertin
solution (i.p.), an indwelling catheter was introduced in the left jugular
vein and externalized on the back 1 week before the clamp. Diet was
restricted 16 h, and mice were placed in a restrainer (Braintree
Scientiﬁc, MA) and underwent a euglycemic clamp with a prime
continuous infusion of human insulin (Humalog, Lilly) at a rate of
24 pmol/kg/min to raise plasma insulin to 0.77 ng/mL. Glucose (15%)
was infused at variable rates to maintain euglycemia. Insulin-stimulated
whole-body glucose ﬂux was estimated using a prime continuous
infusion of HPLC-puriﬁed [3-3H] glucose at a 0.09 mCi/min throughout
the clamp procedure. Blood samples (10 ml) were collected from the tail
vein for plasma [3-3H] glucose determination in 10-min intervals during
the last 30 min [22]. Rates of whole-body glucose appearance (Ra) and
disappearance (Rd) were calculated as the ratio of [3-3H] glucose
infusion rate to the speciﬁc activity of plasma glucose during the last
30 min of the clamp. Hepatic glucose production (HGP) was determined
by subtracting the glucose infusion rate (GIR) from the whole-body Ra
glucose appearance [23]. Additional blood samples were collected to
measure plasma insulin concentrations before and at the end of the
clamp. At the end of experiment, mice were euthanized with Avertin,
and tissues (WAT, liver and muscle) were rapidly removed, frozen in
liquid nitrogen and stored at 80 1C for subsequent analysis.2.9. Statistical analyses
Data were analyzed by one-way ANOVA using SAS software for
Windows release 9.2 (SAS Institute Inc., Cary, NC, USA) on the
W32_VSHOME platform. One-way ANOVA with repeated measures
was performed to assess mean differences between groups for body
weight over time. To test for differences in uterine weights among the
treatment groups, analysis of covariance (ANCOVA) with ﬁnal body mass
as covariates was used. Homogeneity of regression assumptions of the
ANCOVA model were tested and met in each analysis. The Least
Squares Means option using a Tukey–Kramer adjustment was used for
the multiple comparisons among the treatment groups. Data are shown
as the mean7S.E. P values o0.05 are statistically signiﬁcant.MOLECULAR METABOLISM 3 (2014) 177–190 & 2014 The Authors. Published by Elsevier GmbH. Ope3. RESULTS
3.1. TSECs and BZA prevent visceral adiposity
Treatments with E2, CE and their combination as TSECs increased
serum levels of E2 and estrone (E1) – the major component of CE –
respectively (Suppl. Table 1). Compared to sham-operated mice,
vehicle-treated OVX mice exhibited a progressive increase in body
weight characterized by accumulation of intra-abdominal adipose tissue
and adipocyte hypertrophy (Figure 1A–F). All estrogen treatments and
BZA prevented body weight increase, visceral adipose tissue accumula-
tion, and adipocyte hypertrophy. The combination of CE and BZA showed
the greatest impact in OVX mice (Figure 1A–F). Unlike E2 and CE and as
previously reported [5,6], BZA alone did not induce uterine growth (as
assessed by increased tissue weight) (Figure 1G), and when combined
with estrogen, BZA prevented uterine growth with a stronger effect
when combined with CE (Figure 1G). All estrogen treatments suppressed
WAT mRNA expression of lipoprotein lipase (LPL) (Figure 1H), an ER
transcriptional target that promotes uptake of TG into adipocytes [24].
Although BZA treatment alone caused no decrease in LPL mRNA levels,
it did not prevent the suppressive effect of estrogens (CE and E2) on LPL
mRNA (Figure 1H). Together, the data demonstrate that whether alone or
in TSEC combination, BZA exhibits estrogen mimetic action in preventing
adiposity.
3.2. TSECs reverse abnormal serum adipokines and systemic
inﬂammation
Metabolic dysfunction is characterized by recruitment and release of
pro-inﬂammatory cytokines from WAT that cause insulin resistance and
a general, low-grade systemic inﬂammatory state [25]. Serum leptin
levels and the leptin/adiponectin ratio – a marker of insulin resistance
and atherogenesis [26,27] – were signiﬁcantly increased in vehicle-
treated OVX mice relative to sham-operated mice (Table 1). Treating OVX
mice with E2, CE, BZA and TSECs markedly decreased both serum
leptin and the leptin/adiponectin ratio, with the strongest effect observed
in mice treated with CE and CEþBZA, observations that occurred in
parallel to the relative adiposity-preventive effects of these treatments.
In addition, serum levels of RBP4, an adipokine that is elevated in insulin
resistance and type 2 diabetes [28], were reduced in OVX mice by BZA
and estrogen treatment (Table 1). However, CE and BZA, but not E2,
reduced serum levels of Lcn2 (Table 1), an adipokine that is also
elevated in adipose tissue and in serum of obese and insulin resistant
rodents and humans [29,30]. Of note, E2 treatment increased, rather
than reduced, serum Lcn2 levels, and BZA failed to reverse this E2
effect (Table 1). Nonetheless, these drugs exerted a similar effect on
Lcn2 mRNA expression in both liver and WAT (data not shown). Serum
levels of TBARS, a marker of oxidative stress and lipid peroxidation [31],
were signiﬁcantly decreased in OVX mice by E2, CE and TSEC
treatments – but not by BZA alone – compared to the vehicle-treated
OVX mice, thereby demonstrating that estrogens protect against lipid
peroxidation and oxidative stress (Table 1). Thus, the combination of
TSEC with CE improves adipose dysfunction and systemic inﬂammation.
3.3. TSECs and BZA improve hepatic and muscle lipid homeostasis
Consistent with the observation of increased non-alcoholic fatty liver
disease (NAFLD) in menopause [32], vehicle-treated OVX mice exhibited
diffused microvesicular fat inﬁltration in hepatocytes. This observation is
shown by histological analysis (Figure 2A) and resulted from increased
hepatic TG accumulation (Figure 2B). Both the microvesicular fat
inﬁltration in hepatocytes and the hepatic TG accumulation were
signiﬁcantly reduced by all estrogen treatments (Figure 2A and B), with179www.molecularmetabolism.comn access under CC BY-NC-ND license.
Figure 1: TSECs and BZA prevent visceral adiposity. Mice were subjected to sham or OVX surgeries and received the indicated drug treatments for 8 weeks. (A) Body weights, (B) weekly weight
gains and (C) weights of visceral adipose depots (n¼10). (D) Representative H&E stained section of parametrial adipose tissue and distribution histogram of adipocyte size. (E) Average
size of adipocytes and (F) relative adipocyte number (n¼4). (G) Uterine weights. Means are adjusted for final body mass as covariate using the ANCOVA analysis (n¼10). (H) LPL mRNA
expressions from WAT (n¼6). Values represent means7S.E. *Significantly different from all other treatment groups (A) or the OVX vehicle group (B-H) (*Po0.05, **Po0.01, ***Po0.001,
****Po0.0001). †Significantly different from the sham vehicle (Po0.01).
Original article
Treatment group P
Sham OVX
Control E2 CE BZA E2þBZA CEþBZA
Leptin, ng/mL 18.3572.05b 31.1372.22a 5.6970.65c,d 2.0970.66d 9.4771.40c 1.9670.61d 1.4370.22d <0.0001
Adiponectin, μg/mL 14.9970.23a 16.7571.25a 10.4070.36c 11.6870.29b,c 14.0570.53a,b 9.5470.72c 12.0270.49b,c <0.0001
Leptin/adiponectin 1.2370.14b 1.9370.18a 0.5570.06c,d 0.1870.06d 0.6570.09c 0.1970.05d 0.1270.02d <0.0001
RBP4, μg/mL 4.2770.22a,b 4.5970.12a 3.4170.16c,d 3.9470.26a,b,c 3.6670.15b,c 2.8570.16d 3.5470.13b,c,d <0.0001
Lipocalin2, ng/mL 116.4713.8b,c 112.2722.0b,c 284.9765.1a,b 89.8711.5c 70.779.6c 348.4785.0a 80.3714.8c <0.0001
TBARS, nmol MDA/mL 46.470.8a,b 53.673.7a 16.271.2c 37.572.1b 47.773.0a 19.471.5c 22.871.0c <0.0001
Table 1: Serum adipocytokines and TBARS Mice were subjected to sham or OVX surgeries and received the daily drug treatments for 8 weeks. Values represent means7S.E (n¼10).
a–dMeans with different superscripts within the same row are significantly different (Po0.05).a more pronounced beneﬁt associated with CE, compared to E2
treatment (Po0.05). This difference was likely due to the oral CE
delivery that exerts a hepatic ﬁrst pass effect, as opposed to the
transdermal application of E2 [33]. Since the Food and Drug Adminis-
tration recently approved the combination of CE with BZA for treatment
of vasomotor symptoms associated with menopause and prevention of
postmenopausal osteoporosis [14], we continued our focus on CE for the
remainder of this study.
Because estrogen is a powerful suppressor of lipogenesis [3,21], we
assessed gene expression and enzymatic activity of FAS, a key enzyme
in the de novo synthesis of fatty acids [34]. Consistent with hepatic TG
content, vehicle-treated OVX mice showed higher hepatic FAS enzymatic
activity (Figure 2C) that was markedly reduced by CE, BZA and TSEC
treatments in a manner that paralleled their inhibitory effects on FAS
mRNA levels (Figure 2D). Compared to vehicle-treated OVX mice,
hepatic TBARS content paralleled its serum level in that it was
signiﬁcantly lower in CE and CEþBZA-treated groups, but not in those
treated with BZA alone (Figure 2E).
Ectopic lipid accumulation in skeletal muscle – a well-known complica-
tion of estrogen deﬁciency and impaired ERα action – causes insulin
resistance [3]. Accordingly, muscle TG content was higher in vehicle-
treated OVX than vehicle-treated sham mice (Figure 2F). BZA and CE,
alone or together, markedly reduced TG level in skeletal muscle of OVX
mice (Figure 2F).
We next assessed phosphorylation of AMPKα, a major regulator of
glucose and lipid metabolism in liver and skeletal muscle [35].
Compared to vehicle-treated OVX mice, AMPKα phosphorylation in liver
was increased by BZA alone or TSEC, but not by CE alone (Figure 2G
and H). This suggested that increased AMPKα phosphorylation by TSEC
is due to BZA, but not CE. In contrast, AMPKα phosphorylation was not
signiﬁcantly altered in skeletal muscle. Thus, BZA seems to have a
tissue-speciﬁc action to activate AMPKα selectively in liver.
3.4. TSEC and BZA promote lipid oxidation and increase energy
expenditure
To determine the mechanisms mediating the beneﬁcial effects of
estrogen and BZA on tissue lipid accumulation, we examined their
regulation of energy homeostasis by indirect calorimetry. There were no
signiﬁcant differences in food intake (Suppl. Figure 1A) and total daily
locomotor activity (Suppl. Figure 1B) among treatment groups. However,
locomotor activity measured by vertical movements was increased by all
estrogen treatments (Suppl. Figure 1C). Importantly, treatment with CE
and CEþBZA signiﬁcantly enhanced oxygen consumption (VO2) and
increased energy expenditure compared to vehicle-treated mice
(Figure 3A and B). These changes in energy balance were more
pronounced with CE. In addition, BZA alone signiﬁcantly increased VO2MOLECULAR METABOLISM 3 (2014) 177–190 & 2014 The Authors. Published by Elsevier GmbH. Opeand energy expenditure in OVX mice. All treatments produced a
decrease in respiratory exchange ratio (RER), consistent with a
stimulatory effect of all drugs on lipid oxidation and a preference for
fat over carbohydrates as a fuel source (Figure 3C). Interestingly, a
greater decrease in RER was observed in CE-treated mice, and this
correlated with a larger increase in energy expenditure in this group.
These data suggest that estrogen and BZA improve adiposity and
ectopic lipid deposition in muscle and liver, at least in part by increasing
energy expenditure via promotion of fatty acid oxidation.
3.5. CE and BZA promote lipid oxidation via different pathways
To gain insight into the underlying molecular mechanisms promoting
fatty acid oxidation and energy expenditure, we assessed mRNA levels
of selected genes involved in the regulation of thermogenesis and
cellular fuel metabolism in BAT and skeletal muscle (Suppl. Table 2). No
signiﬁcant alterations were detected in BAT or muscle mRNA levels of
uncoupling proteins (UCPs), peroxisome proliferator-activated receptor
gamma co-activator 1α ( PGC1α), or carnitine palmitoyltransferase 1β.
We thus focused on the liver, a major site of lipid oxidation. Fibroblast
growth factor 21 (FGF21), a hepatic hormone secreted during fasting,
plays an instrumental role in inducing hepatic lipid oxidation [36].
Although OVX had no apparent effect on FGF21 hepatic mRNA and
serum concentrations, treating OVX mice with E2 or CE markedly
increased hepatic mRNA and serum concentrations of FGF21 (Figure 3D
and E). Conversely, BZA alone or combined with CE and E2 in TSECs
caused no apparent increase in hepatic FGF21 mRNA expression and
serum concentrations (Figure 3D and E). To ascertain FGF21 systemic
action, we next studied downstream genetic targets of FGF21.
Consistent with enhanced FGF21 systemic action [37,38], mice treated
with CE, E2 and TSEC – but not with BZA alone – exhibited a reduced
mRNA expression of hepatic PPARγ and SCD-1 as well as adipose
FGF21 (Suppl. Figure 2). To determine the mechanism of BZA and TSEC-
induced lipid oxidation in the absence of increased hepatic production of
FGF21, we next studied the expression of two master transcriptional
regulators of hepatic lipid oxidation, sirtuin 1 (SIRT1) and its target, the
peroxisome proliferator-activated receptor-α (PPARα). CE and E2
treatments had no effect on hepatic mRNA expression of either SIRT1
or PPARα (Figure 3F and G). In contrast, BZA and TSECs dramatically
increased hepatic mRNA expression of SIRT1 and PPARα. To conﬁrm
that the increased SIRT1 expression was associated with increased
SIRT1 activity, we quantiﬁed the expression of FGF15 and SHP mRNA,
two genetic markers of FXR action, a target activated by SIRT1 [39].
Both FGF15 and SHP mRNA were increased by BZA but not by E2 or CE
alone (Figure 3H). Further, SIRT1 normally increases the expression
of genes involved in gluconeogenesis, like PEPCK by deacetylating
PGC1α [40]. Accordingly, PEPCK mRNA was also increased by BZA but181www.molecularmetabolism.comn access under CC BY-NC-ND license.
Figure 2: TSECs and BZA improve hepatic and muscle lipid homeostasis. Mice were subjected to sham or OVX surgeries and received the indicated drug treatments for 8 weeks. (A) Representative H&E
stained sections of liver. (B) Liver TG contents (n¼10). (C) Liver FAS enzyme activity (n¼9–12). (D) Liver FAS mRNA expressions (n¼6). (E) Liver TBARS contents (n¼6). (F) Muscle TG contents (n¼10).
Relative phospho-AMPKα (Thr 172) was quantified in (G) liver and (H) skeletal muscle (n¼6). Values represent means7S.E. *Significantly different from the OVX vehicle group (*Po0.05, **Po0.01,
***Po0.001, ****Po0.0001).
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Figure 3: TSEC and BZA promote lipid oxidation and increase energy expenditure via different pathways. OVX mice received the indicated drug treatments for 4 weeks prior to the measurements of (A) O2
consumption, (B) energy expenditure and (C) respiratory exchange ratio (VCO2/VO2) (n¼6). The O2 consumption and energy expenditure were normalized to fat-free mass. In the separate study, mice
were subjected to sham or OVX surgeries and received the indicated drug treatments for 8 weeks. The following measurements were performed in the fed state (D) FGF21 mRNA, (E) serum FGF21
(n¼10), (F) SIRT1 mRNA, (G) PPARα mRNA and (H) mRNAs of FGF15, SHP and PEPCK1 (pck1) (n¼6). mRNA were quantified by Q-PCR for liver samples. Values represent means7S.E. *Significantly
different from the OVX vehicle group (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001).
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Original articlenot by E2 or CE (Figure 3H). Together, these results demonstrate that
BZA enhances SIRT1 expression and downstream hepatic actions
(Figure 3H). Thus, CE and E2 activate hepatic fatty acid oxidation via
FGF21 production, while BZA favors the SIRT1/PPARα pathway. When
estrogens and BZA are combined in TSEC, both the FGF21 and the
SIRT1/ PPARα pathway seem to be activated.
3.6. TSECs and BZA improve glucose and insulin homeostasis
Except for the statistically insigniﬁcant effect of BZA on fed blood
glucose levels, all drug modalities lowered fed and fasting glucose and
insulin levels in OVX mice (Figure 4A–D). Moreover, all treatments
improved glucose tolerance (Figure 4E and F) and decreased insulin
concentrations during glucose tolerance testing (Figure 4G and H), with
a statistically insigniﬁcant lowering effect of BZA on insulin concentra-
tions (Figure 4G and H), suggesting a reversal of insulin resistance. All
drug modalities, including BZA alone, enhanced glucose clearance in
response to exogenous insulin during insulin tolerance testing (ITT)
(Figure 4I and J). It is important to note that BZA alone improved glucose
homeostasis and insulin tolerance to a similar extent as E2 and CE.
Moreover, estrogen treatments reversed adiposity (Figure 1), muscle and
liver lipid accumulation (Figure 2), as well as unfavorable alterations in
adipokines (Table 1) and glucose homeostasis (Figure 4) to a greater
extent in OVX mice than in sham-operated mice. In fact, HFD-fed sham
mice were obese and hyperglycemic compared to sham controls fed a
normal chow diet (Suppl. Figure 3) and HFD-fed OVX mice treated with
estrogens showed improved metabolic homeostasis to levels of controls
fed a normal chow diet. This suggests that the beneﬁcial effects of
estrogens extend to both metabolic abnormalities caused by estrogen-
deﬁciency, as well as on those caused by high fat feeding.
3.7. BZA improves glucose and lipid homeostasis via ERα
Since BZA alone showed estrogen mimetic actions on metabolic
parameters in OVX mice, we used global ERα null mice (ERα / ) to
investigate whether the BZA effect was dependent on ER or the result of
an off-target action (Figure 5). As expected from the previous
experiments, BZA protected OVX wild-type ERαþ /þ mice against
increased body weight, visceral fat depots, elevated serum leptin/
adiponectin ratio and hepatic TG accumulation (Figure 5A–D). In
contrast, BZA protection was lost in OVX ERα / mice (Figure 5
A–D). In addition, BZA improved glucose tolerance (Figure 5E and F) and
insulin sensitivity (Figure 5G and H) in OVX wild-type mice, but failed to
enhance glucose homeostasis in OVX ERα / mice. These ﬁndings
indicate that BZA has estrogen mimetic effects on lipid and glucose
metabolism, and that these act through ERα.
3.8. TSECs but not BZA improve systemic insulin action
In order to determine whether these drugs regulate systemic insulin
action, we performed euglycemic-hyperinsulinemic clamp experiments
in mice treated with CE, BZA, and CE/BZA (TSEC). During the clamp,
plasma insulin levels were raised but remained at physiological levels
that were statistically indistinguishable among treatment groups (Suppl.
Table 3). Compared to vehicle-treated mice, at steady state insulin
levels, the glucose infusion rate (GIR) was signiﬁcantly elevated in OVX
mice treated with CE, TSEC, and to a lesser extent, with BZA (Figure 6A),
indicating a lower effect of BZA on systemic insulin resistance. GIR was
not signiﬁcantly different between BZA and vehicle-treated mice
(Figure 6A). Insulin-stimulated whole body glucose ﬂux (Rd) was
increased in mice treated with CE and TSEC compared to vehicle,
while the modest increase in Rd in BZA-treated mice did not reach184 MOLECULAR METABOLISM 3 (2014) 177–190 & 2014 The Austatistical signiﬁcance (Figure 6B). These observations suggest a modest
increase in overall glucose turnover with BZA compared to CE and TSEC.
Both CE and TSEC, but not BZA, enhanced the ability of insulin to
suppress hepatic glucose production (HGP) (Figure 6C). To further
explore the impact of estrogens on liver glucose metabolism, we
examined pyruvate incorporation into glucose via gluconeogenesis in a
pyruvate tolerance test (PTT) (Figure 6D and E). Mice treated with
estrogen exhibited lower glucose levels than vehicle-treated OVX mice,
as reﬂected by the area under the curve (AUC). In contrast, glucose
levels in BZA-treated mice were similar to those observed in vehicle-
treated OVX mice. These data indicate that CE and TSEC reduce hepatic
glucose output during pyruvate challenge, presumably via suppressing
gluconeogenesis. Taken together, these results demonstrate that CE and
TSEC improve systemic insulin response by enhancing insulin suppres-
sion of HGP and glucose uptake in peripheral tissues. The effect of these
drugs on Rd and HGP could be at least partly mediated by increased
insulin-stimulated Akt phosphorylation in skeletal muscle and liver,
respectively, as suggested by tissues isolated from clamped mice
(Figure 6F and G).
Because the carcinoembryonic antigen-related cell adhesion molecule
(CEACAM1) reduces liver FAS activity when phosphorylated by insulin
[20], we then examined the effect of these drugs on CEACAM1
expression and phosphorylation in liver. OVX produced a minor reduction
in Ceacam1 mRNA in vehicle-treated mice (Figure 6H). Relative to
vehicle-treated OVX mice, CE, TSEC and BZA induced hepatic Ceacam1
mRNA levels (Figure 6H). This translated into an increase in CEACAM1
protein expression and phosphorylation levels in livers derived from pre-
treated OVX mice that had undergone a hyperinsulinemic-euglycemic
clamp (Figure 6I).4. DISCUSSION
Prevention of adiposity by estrogen is mediated primarily by ERα-
dependent mechanisms in the periphery as well as in the central
nervous system [3]. Similar to the effect of estrogen, this study shows
that the anti-adiposity effects of BZA are abolished in ERα-deﬁcient
mice, thereby demonstrating that BZA-associated metabolic actions are
also ERα-dependent. However, the relative contributions of peripheral,
versus central actions of ERα in preventing adiposity during CE therapy
remain unknown. We observe that oral administration of CE and BZA in
estrogen-deﬁcient OVX mice increases lipid oxidation, oxygen consump-
tion and energy expenditure without signiﬁcantly altering food intake or
overall locomotor activity, and importantly, without increasing BAT-
mediated thermogenesis (based on unaltered mRNA levels of genetic
markers in BAT). These ﬁndings are consistent with a recent study
showing that although both subcutaneous and intra-cerebroventricular
administration of E2 increase oxygen consumption and energy expen-
diture in OVX mice, only central E2 administration elevates locomotor
activity, body temperature, and expression of thermogenic markers in
BAT [41]. This suggests that oral administration of CE, BZA, and TSEC
enhances energy expenditure and prevents adiposity in estrogen-
deﬁcient OVX mice independently of central stimulation of sympathetic
outﬂow to BAT by ERα. In support of this notion, little circulating estrone
sulfate is available to the brain following an oral CE administration [42],
and BZA has not been shown to cross the blood brain barrier [43]. Thus,
it is likely that peripherally administered CE and E2 increase lipid
oxidation and energy expenditure largely by engaging peripheral ER
actions, thus increasing basal metabolic rate. Two non-exclusive
mechanisms could mediate this effect. The ﬁrst involves induction ofthors. Published by Elsevier GmbH. www.molecularmetabolism.comOpen access under CC BY-NC-ND license.
Figure 4: TSECs and BZA improve glucose and insulin homeostasis. Mice were subjected to sham or OVX surgeries and received the indicated drug treatments for 4 weeks prior to
the measurements of (A) fed blood glucose, (B) fed plasma insulin, (C) 8-h fasting blood glucose, (D) 8-h fasting plasma insulin, (E) glucose concentrations during OGTT, (F) area under the curve
(AUC) for glucose for (E), (G) insulin concentrations during OGTT and (H) AUC for insulin for (G). (I) Glucose concentrations during the ITT (Week 7) and (J) AUC for glucose during ITT. Values
represent means7S.E. (n¼10). *Significantly different from the OVX vehicle group (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001).
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Figure 5: BZA improves glucose and lipid homeostasis via ERα. Mice were subjected to OVX surgery and received the indicated drug treatments for 8 weeks. (A) Weight gain,
(B) visceral fat depot weights, (C) hepatic TG content, (D) serum leptin/adiponectin ratio. (E) Glucose concentrations during OGTT and (F) area under the curve (AUC) for glucose at
Week 4. (G) Glucose concentrations during the ITT and (H) AUC for glucose at Week 7. Values represent means7S.E. (n¼6). *Significantly different from the corresponding vehicle
groups (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001).
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Figure 6: CE and TSEC improve systemic insulin action. The OVX mice received the indicated drug treatments for 4 weeks and subjected to a euglycemic-hyperinsulinemic clamp for
measurement of (A) GIR, (B) Rd and (C) insulin suppression of HGP (n¼6–9). In the separate study, (D) glucose concentrations were measured during a PTT performed at Week 4; (E) AUC for
glucose during PTT (n¼6). (F) Insulin-stimulated Akt activity was measured in lysates from liver and muscle collected following the clamp study using western blotting of Akt phosphorylation
and expression. (G) Quantification of immunoblot is shown. p-Akt, phosphorylated-Akt; Akt, total Akt (muscle, n¼3; liver, n¼4). In the separate study, sham or OVX mice received the indicated
drug treatments for 8 weeks prior to the measurements of (H) hepatic CC1 mRNA expressions (n¼6). (I) CEACAM1 expression (CC1) and phosphorylation (pCC1) were measured
by Western blotting using lysates from liver collected following the clamp study (n¼4). Values represent means7S.E. *Significantly different from the OVX vehicle group (*Po0.05, **Po0.01,
***Po0.001).
Figure 7: Proposed mechanism of estrogen, BZA and TSEC effects of hepatic lipid metabolism. (A) Estrogen (CE and E2), TSEC and BZA all induce CEACAM1 expression and phosphorylation
thus inhibiting FAS activity and preventing hepatic lipogenesis. (B) CE and E2 promote hepatic lipid oxidation through FGF21 production, thereby elevating basal metabolic rate. In contrast, BZA
promotes hepatic lipid oxidation by increasing SIRT1and PPARα expression as well as increasing AMPK activity. The combination of estrogen and BZA in a TSEC promotes a state of increased
FGF21 production and sensitivity. Altogether, these effects promote lipid combustion in liver that prevents fat storage in skeletal muscle and adipose tissue.
Original articlehepatic production and release of the hormone FGF21 during the fed
state. Treatment with E2 or CE similarly elevates serum FGF21
concentrations to levels normally observed in fasted mice, resulting in
enhanced lipid oxidation and metabolic rate [37,38]. In contract, BZA
does not increase hepatic production of FGF21. Instead, BZA alone or in
TSEC increases hepatic expression and activity of SIRT1, PPARα as well
as hepatic AMPK activity, all known metabolic switches of the fasting
state that promote hepatic lipid oxidation [44–46]. This combined
metabolic switch probably accounts for the retained stimulatory effect of
BZA on lipid oxidation and energy expenditure in the absence of FGF21
release. This may also explain why CE and E2 combined with BZA
increase systemic markers of FGF21 action without apparent increase in
hepatic FGF21 mRNA expression and serum concentrations. We propose
that BZA, by increasing hepatic expression and activity of SIRT1 and
PPARα, sensitizes to FGF21 action thus explaining why FGF21 mRNA
and circulating concentrations remain normal despite enhanced produc-
tion. Thus, the combination of estrogen and BZA in a TSEC promotes a
state of increased FGF21 production and sensitivity without increase in
FGF21 circulating concentrations.
Secondly, E2 and CE could increase β-oxidation through direct ERα action
in skeletal muscle. Muscle-speciﬁc and global ERα null deletions severely
impair fatty acid β-oxidation and cause accumulation of bioactive lipids in
muscle [3,47,48]. Accordingly, the current study shows that CE and BZA
improve ectopic lipid accumulation in skeletal muscle.
Like CE, BZA reduces FAS expression and activity in association with a
decrease in lipid accumulation in liver. This appears to be mediated in
part by inducing CEACAM1 expression and insulin-stimulated phosphor-
ylation, which triggers CEACAM1 binding to and downregulation of FAS
activity [20]. It is unclear whether ER activation by CE and BZA induces
CEACAM1 transcription, or if these drugs induce CEACAM1 by enhancing
insulin signaling, which in turn, activates the transcription of Ceacam1
gene [49]. Of note, the suppression of FAS expression could also be
mediated by ERα suppression of SREBP1c maturation [50,51].
Taken together, these ﬁndings suggest that the anti-obesity effect of CE,
BZA and TSEC in HFD-fed OVX mice result from a combined inhibition of
lipogenesis and stimulation of lipid oxidation. CE, TSEC and BZA all
induce CEACAM1 and inhibit FAS thus preventing hepatic lipogenesis.
However, CE and E2 promote hepatic lipid oxidation at least partially188 MOLECULAR METABOLISM 3 (2014) 177–190 & 2014 The Authrough FGF21 production, thereby elevating basal metabolic rate. In
contrast, BZA and TSEC promote hepatic lipid oxidation via a SIRT1/
PPARα and AMPK pathway. Altogether, this promotes lipid combustion
in liver that prevents fat storage in skeletal muscle and adipose tissue.
Figure 7 summarizes the proposed mechanisms of estrogens and BZA
hepatic action on lipid homeostasis. It should be emphasized, however,
that further studies are needed to study the effect of estrogen on white
fat “browning”, in which certain WAT depots signiﬁcantly acquire the
thermogenic, fat-burning properties of BAT. Further, even though our
data suggest that peripherally administered CE and E2 prevents adipose
accumulation mainly via peripheral ER action, further studies using
tissue-speciﬁc ERα null mice are needed to distinguish ERα-dependent
pathways mediating central versus peripheral regulatory effects of CE
and BZA on metabolism.
Estrogen promotes insulin-stimulated glucose uptake in skeletal muscle
and enhances insulin suppression of hepatic glucose production mainly
through ERα action [48,52–55]. These experiments also show that CE
enhances muscle and liver insulin action during clamp conditions and
importantly, BZA does not antagonize the effect of estrogens on glucose
homeostasis and insulin sensitivity when combined in a TSEC. In fact,
BZA alone improves insulin sensitivity and glucose tolerance in wild-
type, but not ERα null mice, demonstrating that the insulin sensitizing
action of BZA is likely mediated by ERα. Furthermore, BZA enhances the
ability of insulin to clear glucose during an insulin tolerance test. This
likely results from the observed enhanced insulin-stimulated
Akt signaling and improved insulin-mediated glucose disposal in skeletal
muscle. Indeed, we observe a mild positive effect of BZA on glucose
turnover (Rd) in the absence of an effect on insulin suppression of
hepatic glucose production and on pyruvate incorporation into glucose.
Thus, BZA-induced improvement in glucose clearance in response to
insulin is probably due to enhanced insulin action via ERα-dependent
pathways in skeletal muscle. Further studies employing hepatocyte- and
muscle-speciﬁc conditional ERα knockout mice are needed to identify
the mechanisms underlying the metabolic regulatory effect of BZA.
Several lines of evidence suggest a close relationship between Lcn2 and
estrogens. Lcn2 is a putative target gene of estrogens, and Lcn2
deﬁciency results in decreased estrogen production and action [56].
Interestingly, E2, but not CE, increases circulating levels of Lcn2 and itsthors. Published by Elsevier GmbH. www.molecularmetabolism.comOpen access under CC BY-NC-ND license.
expression in white adipose tissue, but BZA did not reverse E2-induced
production of Lcn2. Lcn2 promotes breast cancer progression by
inducing mesenchymal transition through ERα [57], and its over-
expression increases cell migration, invasion, and lung metastasis in
murine breast cancer cells [58]. Although this study did not compare the
efﬁcacy of CE to transdermal E2 in breast cancer treatment, our results
suggest that oral CE (in combination with BZA) may offer a safer
approach than E2 to decrease the risk of breast cancer, at least partly,
by suppressing Lcn2-mediated cancer progression.
In conclusion, our data demonstrate that BZA exhibits estrogen-mimetic
action with regard to glucose and energy homeostasis. More impor-
tantly, they also show that TSECs that combine CE or E2 with BZA
prevent estrogen deﬁciency-induced visceral adiposity, systemic inﬂam-
mation, insulin resistance, and glucose intolerance as efﬁciently as CE or
E2 alone, and importantly, without causing endometrial hyperplasia.
These observations provide novel insights into the mechanisms under-
lying the beneﬁcial effects of TSEC containing BZA with estrogens in
reversing postmenopausal metabolic abnormalities, and suggest that
clinical studies in postmenopausal women are warranted.ACKNOWLEDGMENTS
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